Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer

Elise De Bleser, Phuoc T Tran, Piet Ost

Research output: Contribution to journalReview article

Abstract

Purpose of review To summarize the available literature regarding radiotherapy as a metastasis-directed therapy (MDT) in the treatment of oligometastatic prostate cancer (PCA). Recent findings Three different clinical scenarios of oligometastatic PCA exist in which MDT can be applied: de novo oligometastatic PCA, oligorecurrent PCA, and oligoprogressive PCA. A cut off of three to five metastatic lesions is most often used in these settings. Data from retrospective studies, treating over 1000 patients in total, have been reported. The median progression-free survival ranges between 1 and 3 years, but is influenced by a heterogeneous use of androgen deprivation therapy. For lymph node metastases, a propensity scored matched analysis suggests that cancer specific and overall survival is improved with MDT over standard of care. MDT treatment regimens vary with different radiotherapy techniques, doses, and volumes. Adverse events are limited to grade 1-2 and only rarely grade 3 events are reported. Summary Based on data from retrospective studies, progression-free survival following MDT for oligometastatic PCA is promising with few adverse events. Comparative prospective studies are under way and will shed light on the future of MDT.

Original languageEnglish (US)
Pages (from-to)587-595
Number of pages9
JournalCurrent Opinion in Urology
Volume27
Issue number6
DOIs
StatePublished - Nov 1 2017

Fingerprint

Prostatic Neoplasms
Radiotherapy
Neoplasm Metastasis
Therapeutics
Disease-Free Survival
Retrospective Studies
Standard of Care
Androgens
Lymph Nodes
Prospective Studies
Survival
Neoplasms

Keywords

  • oligometastases
  • prostate cancer
  • stereotactic body radiotherapy
  • whole pelvis radiotherapy

ASJC Scopus subject areas

  • Urology

Cite this

Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer. / De Bleser, Elise; Tran, Phuoc T; Ost, Piet.

In: Current Opinion in Urology, Vol. 27, No. 6, 01.11.2017, p. 587-595.

Research output: Contribution to journalReview article

@article{791606d668554ec0b22e630278f0fa4a,
title = "Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer",
abstract = "Purpose of review To summarize the available literature regarding radiotherapy as a metastasis-directed therapy (MDT) in the treatment of oligometastatic prostate cancer (PCA). Recent findings Three different clinical scenarios of oligometastatic PCA exist in which MDT can be applied: de novo oligometastatic PCA, oligorecurrent PCA, and oligoprogressive PCA. A cut off of three to five metastatic lesions is most often used in these settings. Data from retrospective studies, treating over 1000 patients in total, have been reported. The median progression-free survival ranges between 1 and 3 years, but is influenced by a heterogeneous use of androgen deprivation therapy. For lymph node metastases, a propensity scored matched analysis suggests that cancer specific and overall survival is improved with MDT over standard of care. MDT treatment regimens vary with different radiotherapy techniques, doses, and volumes. Adverse events are limited to grade 1-2 and only rarely grade 3 events are reported. Summary Based on data from retrospective studies, progression-free survival following MDT for oligometastatic PCA is promising with few adverse events. Comparative prospective studies are under way and will shed light on the future of MDT.",
keywords = "oligometastases, prostate cancer, stereotactic body radiotherapy, whole pelvis radiotherapy",
author = "{De Bleser}, Elise and Tran, {Phuoc T} and Piet Ost",
year = "2017",
month = "11",
day = "1",
doi = "10.1097/MOU.0000000000000441",
language = "English (US)",
volume = "27",
pages = "587--595",
journal = "Current Opinion in Urology",
issn = "0963-0643",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer

AU - De Bleser, Elise

AU - Tran, Phuoc T

AU - Ost, Piet

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Purpose of review To summarize the available literature regarding radiotherapy as a metastasis-directed therapy (MDT) in the treatment of oligometastatic prostate cancer (PCA). Recent findings Three different clinical scenarios of oligometastatic PCA exist in which MDT can be applied: de novo oligometastatic PCA, oligorecurrent PCA, and oligoprogressive PCA. A cut off of three to five metastatic lesions is most often used in these settings. Data from retrospective studies, treating over 1000 patients in total, have been reported. The median progression-free survival ranges between 1 and 3 years, but is influenced by a heterogeneous use of androgen deprivation therapy. For lymph node metastases, a propensity scored matched analysis suggests that cancer specific and overall survival is improved with MDT over standard of care. MDT treatment regimens vary with different radiotherapy techniques, doses, and volumes. Adverse events are limited to grade 1-2 and only rarely grade 3 events are reported. Summary Based on data from retrospective studies, progression-free survival following MDT for oligometastatic PCA is promising with few adverse events. Comparative prospective studies are under way and will shed light on the future of MDT.

AB - Purpose of review To summarize the available literature regarding radiotherapy as a metastasis-directed therapy (MDT) in the treatment of oligometastatic prostate cancer (PCA). Recent findings Three different clinical scenarios of oligometastatic PCA exist in which MDT can be applied: de novo oligometastatic PCA, oligorecurrent PCA, and oligoprogressive PCA. A cut off of three to five metastatic lesions is most often used in these settings. Data from retrospective studies, treating over 1000 patients in total, have been reported. The median progression-free survival ranges between 1 and 3 years, but is influenced by a heterogeneous use of androgen deprivation therapy. For lymph node metastases, a propensity scored matched analysis suggests that cancer specific and overall survival is improved with MDT over standard of care. MDT treatment regimens vary with different radiotherapy techniques, doses, and volumes. Adverse events are limited to grade 1-2 and only rarely grade 3 events are reported. Summary Based on data from retrospective studies, progression-free survival following MDT for oligometastatic PCA is promising with few adverse events. Comparative prospective studies are under way and will shed light on the future of MDT.

KW - oligometastases

KW - prostate cancer

KW - stereotactic body radiotherapy

KW - whole pelvis radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85030775222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030775222&partnerID=8YFLogxK

U2 - 10.1097/MOU.0000000000000441

DO - 10.1097/MOU.0000000000000441

M3 - Review article

VL - 27

SP - 587

EP - 595

JO - Current Opinion in Urology

JF - Current Opinion in Urology

SN - 0963-0643

IS - 6

ER -